Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer
Development of chemoresistance in BC is associated with alterations in the tumor secretome, which impairs immune activation and facilitates immunosuppression. Knowledge on the immune microenvironment in residual tumors after standard chemotherapy could aid in selecting rational treatment options for this group of patients.
Authors
- Kotryna Seip (ORCID: https://orcid.org/0000-0001-5936-7294)
- Lina Prasmickaite (ORCID: https://orcid.org/0000-0002-8358-7964)
- Solveig Pettersen
- Shakila Jabeen
- Inger Øynebråten (ORCID: https://orcid.org/0000-0001-8914-5676)
- Alexandre Corthay (ORCID: https://orcid.org/0000-0001-9519-5725)
- Eleni Skourti (ORCID: https://orcid.org/0000-0001-6008-0549)
- Olav Engebraaten (ORCID: https://orcid.org/0000-0002-0986-6957)
- Gunhild M. Mælandsmo (ORCID: https://orcid.org/0000-0002-4797-1600)
- Eivind Valen Egeland (ORCID: https://orcid.org/0000-0002-7273-7277)
- Nadia Mensali (ORCID: https://orcid.org/0000-0002-3130-4352)
- Siri Juell
- Helmut Dolznig (ORCID: https://orcid.org/0000-0002-6063-3585)
- Else Marit Inderberg
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Akershus University Hospital (NO)
- Medical University of Vienna (AT)
- UiT The Arctic University of Norway (NO)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1186/s13058-025-02082-x
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kreftforeningen
- Universitetet i Oslo
- Haukeland Universitetssjukehus